Special Issue

Molecular Biology in Drug Design and Precision Therapy

Message from the Guest Editors

The Special Issue "Molecular Biology in Drug Design and Precision Therapy" aims to explore the interplay between molecular biology and the development of novel therapeutic strategies, with a particular focus on precision medicine. In biomedical research, molecular biology has a tremendous role in elucidating the fundamental mechanisms implicated in disease pathogenesis, simplifying the road to targeted therapies tailored to individual patients. This Special Issue invites contributions that explore the molecular intricacies of disease processes, encompassing a wide array of topics. Emphasizing the molecular level of investigation, manuscripts are encouraged to elucidate the molecular targets of therapeutic interventions, as well as mechanisms of drug action and resistance, and explore the potential of precision medicine approaches to optimize treatment outcomes. Through a comprehensive understanding of molecular mechanisms, this Special Issue aims to drive advancements in drug discovery, development, and personalized therapy, ultimately translating molecular insights into improved clinical outcomes for patients.

Guest Editors

Dr. Cristina Manuela Dragoi

Dr. Ion-Bogdan Dumitrescu

Dr. Alina Crenguța Nicolae

Deadline for manuscript submissions

31 December 2024



Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 2.9
Indexed in PubMed



mdpi.com/si/205719

Current Issues in Molecular Biology MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 cimb@mdpi.com

mdpi.com/journal/ cimb





Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 2.8 CiteScore 2.9 Indexed in PubMed

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Biomedical Science, University of Otago, Christchurch, 2 Riccarton Avenue, P.O. Box 4345, Christchurch 8140, New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.8 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2024).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.

